Treating allergic reactions with anti-IgE antibodies

JP2024544380APending Publication Date: 2024-11-29NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534457
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-14
Filing Date
2022-12-12
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Current treatments for food allergies, particularly anaphylaxis, are limited, often require regular allergen administration, and do not provide comprehensive protection against accidental exposure, with a significant unmet need for safe and effective therapies, especially for children and adolescents.

Method used

Administration of ligelizumab, a humanized monoclonal antibody that binds to IgE with high affinity, blocking its interaction with both high- and low-affinity IgE receptors on mast cells and basophils, thereby reducing allergen sensitivity and preventing allergic reactions.

Benefits of technology

Ligelizumab effectively suppresses free IgE and basophil FcεRI expression, providing dose- and time-dependent protection against allergic reactions and anaphylaxis, with superior pharmacodynamics compared to omalizumab, allowing for safer and more reliable prevention or treatment of IgE-mediated allergic responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544380000001
    Figure 2024544380000001
  • Figure 2024544380000002
    Figure 2024544380000002
  • Figure 2024544380000003
    Figure 2024544380000003
Patent Text Reader

Abstract

The present disclosure relates to methods of modifying the course of an IgE-mediated disease or disorder, particularly such a disease or condition, in a subject having an IgE-mediated allergic response to one or more allergens.
Need to check novelty before this filing date? Find Prior Art